Exercise improves health and physical function in older people, but very few older people participate although the trend is for increasing participation. This study sought to determine whether short duration sprint interval training (SIT) improves health and physical function in older people. Seventeen (9 M and 8 F) older adults (age 66 ± 3 years) were recruited. Participants had blood pressure, physical function and blood lipid profile measured and were then allocated to a control group (CON n = 7) or a SIT group (n = 10). The control group maintained daily activities; the SIT group performed 10 weeks of twice-weekly training sessions of 6-s sprints. By week 10, training sessions lasted 11.6 ± 0.6-min. Ten weeks of SIT resulted in significant changes in pulse pressure (
The main aim of this study was to investigate the influence of consuming a 6% carbohydrate-electrolyte (CHO-E) solution on the intermittent, high-intensity endurance performance and capacity of adolescent team games players. Fifteen participants (mean age 12.7 +/- 0.8 years) performed two trials separated by 3-7 days. In each trial, they completed 60 min of exercise composed of four 15-min periods of part A of the Loughborough Intermittent Shuttle Test, followed by an intermittent run to exhaustion (part B). In a double-blind, randomised, counterbalanced fashion participants consumed either the 6% CHO-E solution or a non-carbohydrate (CHO) placebo (5 ml kg(-1) BM) during the 5 min pre-trial and after each 15-min period of part A (2 ml kg(-1) BM). Time to fatigue was increased by 24.4% during part B when CHO was ingested (5.1 +/- 1.8 vs. 4.1 +/- 1.6 min, P < 0.05), with distance covered in part B also significantly greater in the CHO trial (851 +/- 365 vs. 694 +/- 278 m, P < 0.05). No significant between-trials differences were observed for mean 15-m sprint time (P = 0.35), peak sprint time (P = 0.77), or heart rate (P = 0.08) during part A. These results demonstrate, for the first time, that ingestion of a CHO-E solution significantly improves the intermittent, high-intensity endurance running capacity of adolescent team games players during an exercise protocol designed to simulate the physiological demands of team games.
There is evidence for the physical health benefits of high intensity interval exercise (HIIE), but its public health potential has been challenged. It is purported that compared with moderate-intensity continuous exercise (MICE) the high intensity nature of HIIE may lead to negative affective responses. This systematic review (PROSPERO CRD42017058203) addressed this proposition and synthesised research that compares affective responses to HIIE with MICE and vigorous intensity continuous exercise (VICE), during-, end-, and postexercise. Searches were conducted on five databases, and findings from 33 studies were meta-analysed using random effects models or narratively synthesised. A meta-analysis of affect showed a significant effect in favour of MICE vs HIIE at the lowest point, during and post-exercise, but not at end, and the narrative synthesis supported this for other affective outcomes. Differences on affect between VICE vs HIIE were limited. Pooled data showed arousal levels were consistently higher during HIIE. For enjoyment there was a significant effect in favour of HIIE vs MICE, no difference for HIIE vs VICE at post-exercise, and mixed findings for during-exercise. Although the findings are clouded by methodological issues they indicate that compared to MICE, HIIE is experienced less positively but postexercise is reported to be more enjoyable.
This study compared affective responses to low volume high-intensity interval exercise (HIIE), moderate-intensity continuous exercise (MICE) and high-intensity continuous exercise (HICE). Twelve untrained males ([Formula: see text] 48.2 ± 6.7 ml·kg·min) completed MICE (30 min cycle at 85% of ventilatory threshold (VT)), HICE (cycle at 105% of VT matched with MICE for total work), and HIIE (10 x 6 s cycle sprints with 60 s recovery). Affective valence and perceived activation were measured before exercise, post warm-up, every 20% of exercise time, and 1, 5, 10, and 15 min post-exercise. Affective valence during exercise declined by 1.75 ± 2.42, 1.17 ± 1.99, and 0.42 ± 1.38 units in HICE, HIIE, and MICE, respectively, but was not statistically influenced by trial (P = 0.35), time (P = 0.06), or interaction effect (P = 0.08). Affective valence during HICE and HIIE was consistently less positive than MICE. Affective valence post-exercise was not statistically influenced by trial (P = 0.10) and at 5 min post-exercise exceeded end-exercise values (P = 0.048). Circumplex profiles showed no negative affect in any trial. Affective responses to low volume HIIE are similar to HICE but remain positive and rebound rapidly, suggesting it may be a potential alternative exercise prescription.
SU5416 (Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone; semaxanib) is a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR2). A Phase I dose escalation study was performed. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used as a pharmacodynamic assessment tool. In all, 27 patients were recruited. SU5416 was administered twice weekly by fixed rate intravenous infusion. Patients were treated in sequential cohorts of three patients at 48, 65, 85 110 and 145 mg m À2 . A further dose level of 190 mg m À2 after a 2-week lead in period at a lower dose was completed; thereafter, the cohort at 145 mg m À2 was expanded. SU5416 showed linear pharmacokinetics to 145 mg m À2 with a large volume of distribution and rapid clearance. A significant degree of interpatient variability was seen. SU5416 was well tolerated, by definition a maximum-tolerated dose was not defined. No reproducible changes were seen in DCE-MRI end points. Serial assessments of VEGF in a cohort of patients treated at 145 mg m À2 did not show a statistically significant treatment-related change. Parallel assessments of the impact of SU5416 on coagulation profiles in six patients showed a transient effect within the fibrinolytic pathway. Clinical experience showed that patients who had breaks of therapy longer than a week could not have treatment reinitiated at a dose of 190 mg m À2 without unacceptable toxicity. The 145 mg m À2 dose level is thus the recommended dose for future study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.